ES2636663T3 - Progastrina y patologías hepáticas - Google Patents

Progastrina y patologías hepáticas Download PDF

Info

Publication number
ES2636663T3
ES2636663T3 ES11700114.9T ES11700114T ES2636663T3 ES 2636663 T3 ES2636663 T3 ES 2636663T3 ES 11700114 T ES11700114 T ES 11700114T ES 2636663 T3 ES2636663 T3 ES 2636663T3
Authority
ES
Spain
Prior art keywords
seq
cdr
hvh
hvl
ahx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11700114.9T
Other languages
English (en)
Spanish (es)
Inventor
Jean-François FLOCH
Leïla HOUHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progastrine et Cancers SARL
Original Assignee
Progastrine et Cancers SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine et Cancers SARL filed Critical Progastrine et Cancers SARL
Application granted granted Critical
Publication of ES2636663T3 publication Critical patent/ES2636663T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/595Gastrins; Cholecystokinins [CCK]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES11700114.9T 2010-01-08 2011-01-07 Progastrina y patologías hepáticas Active ES2636663T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29355710P 2010-01-08 2010-01-08
US293557P 2010-01-08
PCT/EP2011/000047 WO2011083089A1 (en) 2010-01-08 2011-01-07 Progastrin and liver pathologies

Publications (1)

Publication Number Publication Date
ES2636663T3 true ES2636663T3 (es) 2017-10-06

Family

ID=43567758

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11700114.9T Active ES2636663T3 (es) 2010-01-08 2011-01-07 Progastrina y patologías hepáticas

Country Status (15)

Country Link
US (1) US8900817B2 (pl)
EP (1) EP2542898B8 (pl)
JP (1) JP5543614B2 (pl)
KR (2) KR101688106B1 (pl)
CN (1) CN102947707B (pl)
AU (1) AU2011204652B2 (pl)
BR (1) BR112012016767A2 (pl)
CA (1) CA2786437C (pl)
EA (1) EA023653B1 (pl)
ES (1) ES2636663T3 (pl)
NZ (1) NZ601593A (pl)
PL (1) PL2542898T3 (pl)
SG (1) SG182332A1 (pl)
WO (1) WO2011083089A1 (pl)
ZA (1) ZA201205002B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10533050B2 (en) * 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy
FR2980196B1 (fr) * 2011-09-16 2013-10-04 Univ Dauvergne Clermont I Principe actif anticancereux issu de guiera senegalensis
KR102197478B1 (ko) 2015-12-31 2021-01-04 프로가스트린 에 캔서스 에스.에이 알.엘. 식도암을 검출 및 치료하기 위한 조성물 및 방법
ES3015244T3 (en) 2015-12-31 2025-04-30 Ecs Progastrin Sa Compositions and methods for detecting and treating ovarian cancer
MA43550A (fr) 2015-12-31 2018-11-07 Syncerus S A R L Compositions et procédés d'évaluation du risque d'apparition d'un cancer
KR102477179B1 (ko) 2015-12-31 2022-12-13 프로가스트린 에 캔서스 에스.에이 알.엘. 위암의 검출 및 치료를 위한 조성물 및 방법
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
SG11201908996YA (en) * 2017-03-30 2019-10-30 Ecs Progastrin Sa Compositions and methods for detecting lung cancer
TW201940881A (zh) * 2018-01-26 2019-10-16 瑞士商Ecs前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
RU2761729C1 (ru) * 2021-04-26 2021-12-13 Вячеслав Леонидович Коробка Способ оценки риска смерти при циррозе печени

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2384519C (en) 1991-03-04 2006-08-15 Bayer Corporation Automated analyzer
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
CA2328501A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Prevention and treatment of hypergastrinemia
US7668661B2 (en) * 2000-04-28 2010-02-23 Siemens Healthcare Diagnostics Inc. Liver disease-related methods and systems
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US7381370B2 (en) 2003-07-18 2008-06-03 Dade Behring Inc. Automated multi-detector analyzer
DK1794586T3 (da) * 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
US20100209426A1 (en) 2006-05-22 2010-08-19 Inserm (Institut National De La Sante Et De La Rec Herche Medicale) Inhibitors of progastrin-induced repression of icat for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/tcf-mediated transcriptional pathway is constitutively active
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP2488551B1 (en) 2009-10-16 2018-07-25 Progastrine et Cancers S.à r.l. Monoclonal antibodies to progastrin and their uses
US10533050B2 (en) 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy

Also Published As

Publication number Publication date
BR112012016767A2 (pt) 2017-09-05
JP5543614B2 (ja) 2014-07-09
CA2786437A1 (en) 2011-07-14
NZ601593A (en) 2014-08-29
EA201200997A1 (ru) 2013-02-28
SG182332A1 (en) 2012-08-30
AU2011204652B2 (en) 2014-04-03
CN102947707A (zh) 2013-02-27
AU2011204652A1 (en) 2012-07-26
EP2542898B1 (en) 2017-05-03
PL2542898T3 (pl) 2017-10-31
KR20140132418A (ko) 2014-11-17
JP2013516617A (ja) 2013-05-13
CN102947707B (zh) 2016-06-01
EP2542898B8 (en) 2017-08-09
CA2786437C (en) 2020-09-01
KR20120102157A (ko) 2012-09-17
WO2011083089A1 (en) 2011-07-14
ZA201205002B (en) 2013-10-30
KR101688106B1 (ko) 2016-12-20
US8900817B2 (en) 2014-12-02
US20110229488A1 (en) 2011-09-22
EP2542898A1 (en) 2013-01-09
EA023653B1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
ES2636663T3 (es) Progastrina y patologías hepáticas
TWI836305B (zh) 抗garp抗體及其製造方法及用途
PE20070183A1 (es) Anticuerpos monoclonales anti-trkb
ES2542757T3 (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide
AR062065A1 (es) Anticuerpo humanizado
RU2011151069A (ru) Анти-axl антитело
NZ581418A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
AR072985A1 (es) Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union
RU2014134747A (ru) Гуманизированные антитела, которые распознают альфа-синуклеин
RU2010133547A (ru) Анти-cldn антитела
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
EP3324996A2 (en) Gdf11 binding proteins and uses thereof
PE20081132A1 (es) Moleculas de adhesion al antigeno que se adhieren a egfr y vectores que los codifican
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
TW200801040A (en) Binding proteins specific for insulin-like growth factors and uses thereof
MX353144B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
AR076030A1 (es) Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
AR082916A1 (es) Moleculas de union a 4-1bb
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
AU2011241483B2 (en) Proteins that bind PI16 and uses thereof
RU2017146220A (ru) Конъюгированные через cys80 иммуноглобулины
EA201270701A1 (ru) Ингибирующие металлопротеины антитела
JP6247646B2 (ja) ヒト化抗hmgb1抗体もしくはその抗原結合性断片